US 12,331,096 B2
Binding domain mapping and compounds, compositions, complexes, methods, and kits related thereto
Lance Liotta, Fairfax, VA (US); Alessandra Luchini Kunkel, Fairfax, VA (US); Amanda Still, Fairfax, VA (US); and Mikell Paige, Fairfax, VA (US)
Assigned to George Mason Research Foundation, Inc., Fairfax, VA (US)
Appl. No. 17/415,190
Filed by GEORGE MASON RESEARCH FOUNDATION, INC., Fairfax, VA (US)
PCT Filed Jan. 3, 2020, PCT No. PCT/US2020/012196
§ 371(c)(1), (2) Date Jun. 17, 2021,
PCT Pub. No. WO2020/142700, PCT Pub. Date Jul. 9, 2020.
Claims priority of provisional application 62/788,214, filed on Jan. 4, 2019.
Prior Publication US 2022/0064259 A1, Mar. 3, 2022
Int. Cl. C07K 14/705 (2006.01); A61K 38/00 (2006.01); A61P 35/00 (2006.01); C07C 303/22 (2006.01); C07C 309/50 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); G01N 33/68 (2006.01)
CPC C07K 14/70532 (2013.01) [A61P 35/00 (2018.01); C07C 303/22 (2013.01); C07C 309/50 (2013.01); C07K 7/06 (2013.01); C07K 7/08 (2013.01); C07K 14/70521 (2013.01); G01N 33/6845 (2013.01); A61K 38/00 (2013.01)] 5 Claims
 
1. A peptide comprising the amino acid sequence set forth as:
CYRAMISYGGADYKRITC (SEQ ID NO:2);
CLKYDAPAFTVTC (SEQ ID NO:4); or
CLNWYRMSPSNQTDKLAAC (SEQ ID NO:7).